Health Care sector stocks

XLV stock price: $85.21 -3.80% At close on Apr 1st, 2020

Health Care sector definition

The healthcare sector consists of companies that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare to patients.

Health Care sector is composed of 853 companies with a total market capitalization of $4.95 tn

Health Care companies

Aytu BioScience, Inc. (AYTU)

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States.The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.

  • Industry: Major Pharmaceuticals
  • Country:
  • Market cap: $12.88 M
  • 3M gains: +53.00 %
  • Avg. Volume: 72.3 M

Astrazeneca PLC (AZN)

AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.Its marketed products comprise Arimidex, Casodex\u002FCosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1\u002FAtacand HCT\u002FAtacand Plus, Brilinta\u002FBrilique, Crestor, Imdur, Plendil, Seloken\u002FToprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga\u002FForxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp\u002FDaxas, Duaklir Genuair, Eklira Genuair\u002FTudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler\u002FPulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra\u002FFluMist Quadrivalent and Synagis for infection diseases; Movantik\u002FMoventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec\u002FPrilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. It has collaboration agreements with Valeant Holdings Ireland, Eli Lilly and Company, FibroGen, Astellas, Pieris Pharmaceuticals Inc, Champions Oncology, Inc., Moderna Therapeutics, Takeda Pharmaceutical Company Limited, and Chembio Diagnostics, Inc.; definitive agreement with Foundation Medicine, Inc.; a clinical trial collaboration agreement with G1 Therapeutics, Inc.; collaboration and license agreement with Celgene International Sàrl; and a license agreement with LEO Pharma A\u002FS. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

  • Industry: Major Pharmaceuticals
  • Country: United Kingdom
  • Market cap: $101.32 bn
  • 3M gains: -10.82 %
  • Avg. Volume: 19.5 M

Baxter International Inc. (BAX)

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments.It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $38.55 bn
  • 3M gains: -7.76 %
  • Avg. Volume: 15.2 M

Biomerica, Inc. (BMRA)

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide.The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $23.96 M
  • 3M gains: +149.11 %
  • Avg. Volume: 5.5 M

Audentes Therapeutics, Inc. (BOLD)

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States.The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $1.02 bn
  • 3M gains: +123.35 %
  • Avg. Volume: 5.7 M

Celgene Corporation (CELG)

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide.It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST\u002FIMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $63.57 bn
  • 3M gains: +15.16 %
  • Avg. Volume: 32.7 M

Corindus Vascular Robotics, Inc. (CVRS)

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures.The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise, robotic-assisted control of coronary guide catheters, guidewires, and balloon\u002Fstent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force and distributor relationships in the United States and internationally. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. The company is headquartered in Waltham, Massachusetts.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $239.98 M
  • 3M gains: +78.66 %
  • Avg. Volume: 15.4 M

Express Scripts Holding Company (ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe.It operates in two segments, PBM and Other Business Operations. The PBM segment offers clinical solutions, specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, administration of a group purchasing organization, and consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; and Express Scripts SafeGuardRxSM, a suite of solutions targeting the medication classes that pose a budgetary threat to its clients. The Other Business Operations segment distributes pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare\u002Forphan diseases. This segment also provides consulting services, such as design, implementation, and project management for pharmaceutical and biotechnology manufacturers to collect scientific evidence to guide the use of medicines. The company serves care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2016, it operated four automated dispensing home delivery pharmacies; one non-automated dispensing home delivery pharmacy; and one non-dispensing home delivery pharmacy, as well as various non-dispensing order processing and patient contact centers, specialty drug pharmacies, and fertility pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

  • Industry: Medical/Nursing Services
  • Country: USA
  • Market cap: $51.61 bn
  • 3M gains: -2.38 %
  • Avg. Volume: 22.2 M

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East.The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera\u002FEviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan\u002FRapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV\u002FAIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology\u002Foncology; cardiovascular; and inflammation\u002Frespiratory diseases. The company markets its products through its commercial teams and\u002For in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $85.09 bn
  • 3M gains: +12.47 %
  • Avg. Volume: 89.2 M

Aevi Genomic Medicine, Inc. (GNMX)

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States.Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II\u002FIII SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $15.9 M
  • 3M gains: +30.77 %
  • Avg. Volume: 7.8 M

Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States.The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $46.08 M
  • 3M gains: +12.77 %
  • Avg. Volume: 58.0 M

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast\u002Flung\u002Fpancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $351.83 M
  • 3M gains: +158.39 %
  • Avg. Volume: 126.1 M

Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas MD Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $1.22 bn
  • 3M gains: +9.40 %
  • Avg. Volume: 8.6 M

Johnson & Johnson (JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $360.22 bn
  • 3M gains: -10.16 %
  • Avg. Volume: 48.1 M

Kala Pharmaceuticals, Inc. (KALA)

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology.The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $244 M
  • 3M gains: +117.49 %
  • Avg. Volume: 6.3 M

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases.Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib\u002FII clinical study in combination with backbone treatments for relapsed\u002Frefractory multiple myeloma; Phase II\u002FIII clinical trial for patients with relapsed and\u002For refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II\u002FIII clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I\u002FII study for patients with relapsed\u002Frefractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $534.83 M
  • 3M gains: -0.88 %
  • Avg. Volume: 8.0 M

Merck & Company, Inc. (MRK)

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Aduro Biotech, Inc.; Premier Inc.; Cancer Research Technology; Corning; Pfizer Inc.; AstraZeneca PLC.; SELLAS Life Sciences Group Ltd.; and Aeglea BioTherapeutics, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $205.27 bn
  • 3M gains: -18.30 %
  • Avg. Volume: 61.9 M

Moderna, Inc. (MRNA)

  • Industry: Biotechnology
  • Country:
  • Market cap: $6.47 bn
  • 3M gains: +57.07 %
  • Avg. Volume: 57.5 M

Novavax, Inc. (NVAX)

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants.The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $842.27 M
  • 3M gains: +215.99 %
  • Avg. Volume: 37.8 M

Novartis AG (NVS)

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; and Bill & Melinda Gates Foundation. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

  • Industry: Major Pharmaceuticals
  • Country: Switzerland
  • Market cap: $205.74 bn
  • 3M gains: -11.48 %
  • Avg. Volume: 12.7 M

Health Care sector performance

After boosting an amazing 7.39% in a week last week, Healthcare sector ETF closed this week at $87.57 and rose a pretty good 3.04%. By mid March XLV plunged a hair-raising -14.62% in just one week.

Not so far away is the last price record Healthcare sector ETF marked late January, but since then it dropped a 16.26%. Since price and 40-weeks moving average lines crossed down early March, XLV fell $-9.11 per share (-9.42%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since late May 2019 when SMA20w and SMA40w crossed up, XLV price gained $0.12 per share (0.14%).

Healthcare sector ETF performance
3 months-15.42 %
6 months-3.99 %
1 year-5.14 %

Health Care sector industries

Industry
Biotechnology
Hospital/Nursing Management
Industrial Specialties
Major Pharmaceuticals
Medical Electronics
Medical Specialities
Medical/Dental Instruments
Medical/Nursing Services
Ophthalmic Goods
Other Pharmaceuticals
Precision Instruments

Novartis stock

The featured stock this month is Novartis, a leading pharma company that markets a range of healthcare products worldwide. Novartis stock made all-time highs last July, and since then the share has been sliding progressively and it's now down close to 10% from ATH.

Top performing stocks in the Health Care sector

Company3M gain6M gain
Aetna+6.47 %+21.07 %
Array+106.52 %+149.22 %
Forty Seven+148.87 %+1,480.13 %
The Medicines+65.98 %+129.65 %